Insider Trading Activity For Crinetics Pharmaceuticals Inc (NASDAQ:CRNX)
Vivo Capital Fund Viii, L.P. , Major Shareholder of Crinetics Pharmaceuticals Inc (NASDAQ:CRNX) reportedly Sold 417,000 shares of the company’s stock at an average price of 22.25 for a total transaction amount of $9,278,250.00 SEC Form
Analyst Ratings History For Crinetics Pharmaceuticals Inc (NASDAQ:CRNX)
- On 8/13/2018 Piper Jaffray Companies Initiated Coverage of rating Overweight with a price target of $40.00
- On 8/13/2018 Leerink Swann Initiated Coverage of rating Outperform with a price target of $43.00
- On 11/14/2018 JPMorgan Chase & Co. Lower Price Target of rating Neutral to Neutral with a price target of $29.00 to $28.00
- On 2/14/2019 HC Wainwright Initiated Coverage of rating Buy with a price target of $35.00
- On 3/11/2019 Cantor Fitzgerald Initiated Coverage of rating Overweight with a price target of $40.00
Recent Trading Activity for Crinetics Pharmaceuticals Inc (NASDAQ:CRNX)
Shares of Crinetics Pharmaceuticals Inc closed the previous trading session at with 24.86 shares trading hands.
